Europe
The current Spinraza cost is $750,000 for the first year and $375,000 for every year after for the life of the patient. It is approved for all forms of SMA.
Partnering with Hong Kong-based Sinovant Sciences, which is one of Ramaswamy’s “vant” companies, Roivant and Sinovant are launching a company called Cytovant Sciences.
Human cells have a sophisticated regulatory system at their disposal: labeling proteins with the small molecule ubiquitin.
Karolinska Development’s portfolio company Aprea presents results from studies with APR-246 in combination with immune checkpoint blockade.
Across the globe, pharma and biotech companies report deals and pipeline updates, with news from Boehringer Ingelheim, Metrion, Elvie, and more.
ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.
World’s first blood test for endometriosis can detect up to 9 out of 10 cases
Two global leaders create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers
CENTOGENE announced that Dr. Flemming Ornskov has been appointed to the Supervisory Board and has been elected Non-Executive Chairman. His appointment is effective April 1, 2019.
In 1979, Evonik launched the thermoplastic elastomer polyether block amide (PEBA) under the brand name VESTAMID® E from its largest global production site in the Marl Chemical Park.
PRESS RELEASES